Menu
Search
|

Menu

Close
X

Vital Therapies Inc VTL.OQ (NASDAQ Stock Exchange Global Select Market)

5.03 USD
+0.08 (+1.52%)
As of Feb 16
chart
Previous Close 4.95
Open 4.95
Volume 57,802
3m Avg Volume 36,227
Today’s High 5.10
Today’s Low 4.85
52 Week High 6.65
52 Week Low 2.25
Shares Outstanding (mil) 42.21
Market Capitalization (mil) 212.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.976
FY16
-1.304
FY15
-2.102
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
--
8.57
Price to Book (MRQ)
vs sector
3.42
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
0.00
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
-75.75
13.54
Return on Equity (TTM)
vs sector
-75.82
14.80

EXECUTIVE LEADERSHIP

Faheem Hasnain
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Russell Cox
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Michael Swanson
Chief Financial Officer, Since 2013
Salary: $94,791.00
Bonus: $20,854.00
Robert Ashley
Executive Vice President, Chief Technical Officer, Since 2013
Salary: --
Bonus: --
Duane Nash
Executive Vice President, Chief Business Officer, Since 2013
Salary: $350,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

15010 Avenue of Science Ste 200
SAN DIEGO   CA   92128-3421

Phone: +1858.6736840

Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company's ELAD System consists of approximately four disposable ELAD C3A cell cartridges.

SPONSORED STORIES